All filters
Slidesets
Integrating science, logistics and cost in approval of hierarchical testing strategies for NASH - The payer's perspective- Robert LoNigro, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Pathways and priorities for biomarker assessment- Peter Stein, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Repeatability, reproducibility and analytic standards for biomarker development- Abbas Bandukwala
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Linking “intended use” to evidence needed for bringing a biomarker to market- John Sninsky, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Reporting standards: STARD & TRIPOD- Patrick Bossuyt, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Quality standards for imaging studies- Claude Sirlin, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Case definitions for use as reference standards- Mohammed Siddiqui, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Defining the reference standard for biomarker development - Histology versus clinical outcomes- Kathleen Donohue, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
A Context of Use Framework for Bioanalytical Validation of the CK18 Apoptosis Biomarker for NASH Drug Development- Sumit Kar
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Serum markers of collagen formation are associated with the severity of Liver fibrosis and Non-Alcoholic Steatohepatitis (NASH) histological features and to impaired renal function (IRF) in a NAFLD cohort- Samuel Daniels
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
What is needed to link device approval to clinical application approval?- David Litwack, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Algorithm to identify non-alcoholic steatohepatitis (NASH) patients with a NAS≥4 and F≥2: algorithm derived in an American screening cohort and validation in a British non-alcoholic fatty liver disease (NAFLD) cohort- Celine Fournier
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Study design to validate biomarkers of therapeutic response for pre-cirrhotic NASH- Brent Tetri, MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Study design to validate biomarkers of therapeutic response in cirrhosis due to NASH- Detlef Schuppan, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Defining therapeutic response in precirrhotic and cirrhotic NASH- Manal Abdelmalek , MD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
The clinical need for integrated assessment of NASH diabetes and heart disease- Arun Sanyal, MD, MBBS
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Use of plasma PRO-C3, PRO-C5, and PRO-C6 for the diagnosis and follow-up of fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD)- iana Leeming
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Neoepitope fragments of extracellular matrix as markers of fibrosis in chronic liver disease: Insights into clinical and preclinical utilization for unfolding disease pathogenesis - Diana Leeming, PhD
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Feasibility of Using Deep-learning-based Techniques for Liver Couinaud Segmentation and Proton Density Fat Fraction (PDFF) Estimation- Hashem Almahmoud
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
Repeatability and Reproducibility of Multiparametric Magnetic Resonance Imaging of the Liver- Andrea Dennis
Presented at:
International Workshop on NASH Biomarkers 2018
Slidesets
FDA perspective on parallel review (Not available)- Rochelle Fink, MD, JD
Presented at:
International Workshop on NASH Biomarkers 2018